The cell atlas that skipped children, and the $38.5 million effort to fill the gap

In 2017, Deanne Taylor attended a presentation at the University of Pennsylvania unveiling the Human Cell Atlas, a project to map every cell in the human body, and learned as details emerged that its researchers had made plans to study only adults ^[1][2]. That omission is a data problem with a dosing consequence: children's cells differ from adults' in how they express genes, switching them on and off or turning them up and down, and those variations can cause drastically different and even deadly responses to drugs that adults tolerate well ^[3][4].

The default assumption Taylor describes is the familiar one, that children are exactly like small adults ^[5]. She had joined the Children's Hospital of Philadelphia as director of bioinformatics three years before the talk, in 2014, and had already been disappointed by how little investment went to medical research focused on children ^[6][7][8].

What followed was committee work rather than laboratory work, which is usually how gaps like this get closed. Taylor joined the Human Cell Atlas's volunteer team and helped write a section on children into the white paper setting out the group's goals and plans ^[9]. She assembled a cross-hospital coalition of pediatric researchers to contribute, then led a 2019 paper making the case for studying children, intended to draw interest and funding ^[10]. "It put a flag in the ground," she says ^[11].

Four years after the talk, in 2021, the NIH awarded $38.5 million to the Developmental Genotype-Tissue Expression Project, or dGTEx, aimed at building the first comprehensive database of healthy pediatric tissue ^[12][13]. The supply side is the part worth sitting with: the project banks samples collected from otherwise healthy children who have died and whose parents agreed to donate their bodies, and maps gene expression across all the major organ systems ^[14].

The division of labor is unglamorous and load-bearing. Taylor and her team curate and standardize the information attached to each donation, including family history and details about the samples, while a separate group analyzes the samples themselves; the two streams are then combined into a database intended as a baseline of what gene expression looks like in children ^[15][16]. That baseline is described as a first step toward research on normal development, disease, and drug effectiveness ^[17]. The dGTEx data will eventually feed into the Human Cell Atlas, which now includes a pediatric section ^[18].

Sarah Teichmann, a cofounder of the Human Cell Atlas, credits Taylor with insisting on scope: "We don't just need to understand the pediatric kidney or the pediatric brain or the pediatric immune system. We need a holistic view of pediatric development" ^[19]. The atlas depends on a loose coalition of researchers each pursuing their own objectives, which is exactly the condition under which standardized metadata either exists or the merged dataset is unusable ^[20].

The MIT Technology Review profile does not report how many donations dGTEx has banked, when the database will be released, or name a drug whose pediatric response diverges ^[21]. Those are the numbers to ask for. Watch whether the curation standards survive the merge into the Human Cell Atlas, whether the pediatric section attracts funding beyond this single grant, and whether any of it eventually reaches a label change rather than stopping at a reference database.